Silence Therapeutics PLC reports a Return on Equity (ROE) of -172.41%.

What is SLN's dividend yield?

Silence Therapeutics PLC offers a dividend yield of 0.00%.

What is SLN's Quality Score?

Our AI rates SLN's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy SLN?

Our AI Timing Score for SLN is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does SLN belong to?

Silence Therapeutics PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Silence Therapeutics PLC (SLN) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

SLN AI Analysis Summary

Our AI summary for SLN: Silence Therapeutics PLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -172.41%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

SLN

Silence Therapeutics PLC

US:NASDAQ STOCK Healthcare >> Biotechnology News 75

USD 11.17

0.49 (4.59%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-172.4%

ROE

-74.0%

ROA

0.00%

Div Yield

SILENCE THERAPEUTICS PLC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 11.17 Price 0.49 (4.59%) Day Change	NEWS SCORE: 75

SLN, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	75
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	11.17
PBV / Sector	10.21 / 44,022.72
Earning Per Share	-1.89

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	5.65 M GREAT
Average 1W Daily Value	6.63 M

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-9,243.05 / 98.24
NPM Average (%) / Sector	-5,120.52 / -1,697.63
NPM Change Average (%) / Sector	3,731.85 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-73.99 / 185,260.96
ROA Average (%) / Sector	-48.75 / 36,684.70
ROA Change Average (%) / Sector	30.71 / 422,221.66 GREAT
ROE (%) / Sector	-172.41 / 243,762.23
ROE Average (%) / Sector	-147.91 / 48,758.47
ROE Change Average (%) / Sector	46.18 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:51
Symbol	SLN
Name	SILENCE THERAPEUTICS PLC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	47.23 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	504.47 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 12 Hammersmith Grove, London, United Kingdom, W6 7AP

Phone: 44 20 3457 6900

Website: https://www.silence-therapeutics.com

Employees: 88

Sector: Healthcare >> Biotechnology

Description: Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.